BRAINSTORM CELL THERAPEUTICS INC.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

BCLI$1.14-7.3%Stored close · as of Jul 8, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. FORM 10-K SUMMARY

Not applicable

SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BRAINSTORM CELL THERAPEUTICS INC.
Date: March 31, 2025	By:	/s/ Chaim Lebovits
		Name: Chaim Lebovits
		Title: Chief Executive Officer

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Chaim Lebovits	Chief Executive Officer	March 31, 2025
Chaim Lebovits	(Principal Executive Officer)
/s/ Alla Patlis	Interim Chief Financial Officer and Controller	March 31, 2025
Alla Patlis	(Principal Financial and Accounting Officer)
/s/ Irit Arbel		March 31, 2025
Irit Arbel	Director
/s/ Nir Naor		March 31, 2025
Nir Naor	Director
/s/ Jacob Frenkel		March 31, 2025
Jacob Frenkel	Director
/s/ Anthony Polverino		March 31, 2025
Anthony Polverino	Director
/s/ Uri Yablonka		March 31, 2025
Uri Yablonka	Director

/s/ Menghisteab Bairu		March 31, 2025
Menghisteab Bairu	Director

/s/ Stacy Lindborg		March 31, 2025
Stacy Lindborg	Director

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.